Macro CD5L deteriorates CD8T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB and CD8 proliferating proportions and a low Macro CD5L proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB and CD8 proliferating proportions are increased, but the CD8 GZMK proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB to CD8 GZMK facilitates good response to the therapy, while Macro CD5L-CD8 GZMB crosstalk impairs the response by increasing CTLA4 in CD8 GZMB. Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8T-cell status conversion and exhaustion induced by Macro CD5L in influencing the response, suggesting future avenues for cancer treatment optimization.